Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

PHASE I/II CLINICAL TRIAL OF SYS6052 (RECOMBINANT HERPES ZOSTER VIRUS VACCINE (CHO CELLS)) OFFICIALLY INITIATED IN CHINA

The Board of Directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the Phase I/II clinical trial of SYS6052, a recombinant herpes zoster virus vaccine (Chinese Hamster Ovary ("**CHO**") cells) (the "**Product**") developed by the Group, has been officially initiated in China.

The Product is a recombinant protein vaccine developed by the Group, consisting of the varicella-zoster virus glycoprotein E (gE) protein antigen and a novel nano-adjuvant system independently developed by the Group. Through the optimisation of the antigen and nano-adjuvant system, the Product can induce robust humoral and cellular immune responses.

In July 2026, the Group received the Notice of Approval for Clinical Trial of Drug issued by the National Medical Products Administration of the People's Republic of China. Following the approval, the Group initiated a randomised, blinded, controlled Phase I/II clinical trial, aiming to evaluate the safety and immunogenicity of the Product administered to individuals aged 40 years and over. Currently, the recruitment and screening of participants for the clinical trial are actively underway.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 2 November 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.